32.2 C
Vientiane
Thursday, May 22, 2025
spot_img
Home Blog Page 616

HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Feb. 26, 2025 /PRNewswire/ — HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders.

Under the agreement, the partner gains exclusive global rights, excluding Greater China (mainland China, Taiwan, Hong Kong, and Macau), to develop and commercialize HAT001 (designated as HBM9013 by Harbour BioMed), a potent and selective anti-CRH-neutralizing antibody. In return, HBMAT is eligible to receive up to $395 million, including upfront, development, regulatory and commercial milestone payments, as well as tiered royalties on future net product sales. Additionally, HBMAT is also entitled to a warrant to receive minority interest in the partner.

HAT001/HBM9013 is designed to neutralize CRH for various disorders, including congenital adrenal hyperplasia (CAH). CAH is a group of autosomal recessive diseases due to mutations in genes that encode for enzymes necessary for synthesis of key adrenal hormones, which lead to serious health consequences. Current standard of care therapy of CAH was introduced more than 70 years ago. It has not changed significantly since and still has huge unmet medical needs. HAT001/HBM9013 aims to dramatically improve standard of care and improve patient outcomes. It has demonstrated strong preclinical efficacy in downregulating CRH-mediated induction of adrenocorticotropic hormone (ACTH) and is being advanced toward clinical development.

“This collaboration represents a pivotal step for HBMAT in our mission to deliver innovative solutions for patients facing challenging endocrine disorders. The completion of this transaction also marks Harbour BioMed’s partial exit from the first global NewCo we incubated,” said Dr. Jingsong Wang, Founder, Chairman & CEO of Harbour BioMed, and Chairman of BOD of HBMAT. “HAT001/HBM9013 has the potential to be a transformative therapy. With their expertise in drug development, our partner is well-positioned to help bring this therapy to patients worldwide.”

About HBM Alpha Therapeutics

HBM Alpha Therapeutics is a company presently developing antibody therapeutics aimed at the rare genetic disease congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Its therapeutics could also be indicated for other endocrinological diseases related to the dysregulation and function of the hypothalamus-pituitary-adrenal (HPA) axis.

HBMAT was founded and incorporated in Delaware, USA in 2019. It is a joint venture between Harbour BioMed and Boston Children’s Hospital, an affiliate of Harvard Medical School. For more information, please visit www.hbmalphatx.com.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.
 
The proprietary antibody technology platforms Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, and HBICE® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to www.harbourbiomed.com.

Tenchijin Selected as Data Service Provider of Japan Space Agency’s Advanced Land Observing Satellite-4 (ALOS-4)

TOKYO, JAPAN – Media OutReach Newswire – 26 February 2025 – Tenchijin, Inc. (Chuo-ku, Tokyo, CEO: Yasuhito Sakuraba), a Japanese satellite tech company endorsed by the Japan Aerospace Exploration Agency JAXA, has been selected as a data service provider to utilize the PALSAR-3 observation data of Advanced Land Observing Satellite-4 “DAICHI-4”(ALOS-4), which is carried out by Space Technology Directorate I of JAXA. Tenchijin will provide data services to the general public using ALOS-4 observation data until March 2028.

Tenchijin Selected as Data Service Provider of Japan Space Agency's Advanced Land Observing Satellite-4 (ALOS-4)
Tenchijin Selected as Data Service Provider of Japan Space Agency’s Advanced Land Observing Satellite-4 (ALOS-4)

This will be the first online sale¹ of such data in Japan and will enable anyone to easily and immediately purchase the data of their interest in a small area at a low price. The timing of the service will be announced shortly.

¹Users can select data, place orders, and make payments all online.

About Advanced Land Observing Satellite-4 “DAICHI-4”(ALOS-4)

The Advanced Land Observing Satellite-4 (ALOS-4) is a satellite that observes Earth’s surface using its onboard phased array type L-band synthetic aperture radar (PALSAR-3). The L-band radar technology has continuously been developed in Japan. With further improved observation performance compared to the predecessor PALSAR-2 aboard the DAICHI-2 (ALOS-2), JAXA and its prime contractor, Mitsubishi Electric Corporation, are developing the satellite, aiming to achieve both high resolution and a broader observation swath.
Unlike observations by an optical sensor, radar images can be acquired day and night, as it does not require sunlight. Moreover, since radio waves can penetrate clouds, the images can be obtained regardless of weather conditions. The ALOS-4 will leverage these merits for observing and monitoring disaster-hit areas, forests, and sea ice. In addition, it will also challenge new areas, such as monitoring infrastructure displacement.

Reference: https://global.jaxa.jp/projects/sat/alos4/

About the Public Solicitation for Data Service Provider Using Observation Data of ALOS-4

JAXA aims to provide data and services to the general public, mainly through the private sector, as part of its efforts to expand the ALOS-4 observation data and service business through public-private partnerships.

This time, as part of the public solicitation for the selection of the private-sector operator, JAXA requested proposals for a project to provide ALOS-4 data to general users until FY2027. Proposals were requested to include an outline of the project, including a mechanism for general users to access ALOS-4 observation data, a project concept and vision, a schedule and implementation structure, and other information such as the price for providing data services.

Reference: https://www.satnavi.jaxa.jp/ja/news/2024/07/30/9597/index.html

Tenchijin’s Thoughts on the Space Industry

Tenchijin has launched a new initiative to expand the use of satellite data in Japan. Satellite data has the power to solve social issues in a wide range of fields, including agriculture, disaster prevention, urban planning, and energy. However, in Japan, issues such as technical hurdles, cost, and lack of awareness have hindered the spread of data. The goal of Tenchijin is to change this situation and transform satellite data from something special to something familiar.

ALOS-4, launched by JAXA in 2024, will play an innovative role in the fields of crustal deformation, disaster prevention, forest management, and agriculture with the world’s highest resolution and observation coverage. For example, in disaster-prone Japan, the ability to observe at night and under bad weather conditions can be utilized to quickly assess damage from heavy rainfall and earthquake disasters. In addition, the system is expected to be used in a variety of ways toward a sustainable society, such as estimating forest carbon stocks and determining crop acreage in the agricultural sector.

Tenchijin will make the data provided by ALOS-4 available to as many people as possible. First, Tenchijin will provide an intuitive platform that is easy for anyone to use, enabling data analysis without special knowledge. In addition, Tenchijin will develop a service model with low introduction costs to create an environment in which small and medium-sized companies and local governments can easily utilize the service. Furthermore, Tenchijin will proactively disseminate best practices and work to ensure that the value of satellite data is widely recognized.

In addition, Tenchijin will focus on human resource development through training and workshops to broaden the base of professionals who can handle data. Tenchijin will also work with local governments, private companies, and educational institutions to build an ecosystem that can solve social issues from a variety of perspectives.

The power of data will change the future. Based on this belief, Tenchijin will do its utmost to realize a sustainable future by maximizing the power of satellite data.

About Tenchijin COMPASS

In July 2022, Tenchijin released a free plan for its land evaluation engine, Tenchijin COMPASS. Tenchijin COMPASS is a land evaluation service that comprehensively analyzes, visualizes, and provides data based on various data, including big data from earth observation satellites. It can be customized for various purposes, from agricultural production to urban development, and it can find the best land for business from space.

Many people think of satellite data as photos taken from satellites. Images taken from satellites are typical satellite data, but Tenchijin COMPASS can also obtain weather information such as precipitation, topographical information represented by 3D maps, and surface temperatures observed by infrared light anywhere in the world.

Tenchijin COMPASS also allows to overlay ground data and performance data that are already available to perform composite analysis.

How to use Tenchijin COMPASS

・Cost: free
・Supported languages: English, Japanese
・Supported browsers: Google Chrome recommended, PC only
・Website URL: https://tenchijin.co.jp/compass/
Contact: info-compass@tenchijin.co.jp

Hashtag: #Tenchijin #Space #SatelliteTechnology #Sustainability




The issuer is solely responsible for the content of this announcement.

Tenchijin, Inc.

E-Mail: (person in charge of communication: Keisuke Sunagare)
Address: THE EAST Nihonbashi 1-chome ROOM13, 5th floor, Mitsui Building, 1-4-1 Nihonbashi, Chuo-ku, Tokyo
Representative: Yasuhito Sakuraba, CEO
Business content: land evaluation consulting using satellite data
Business activities: land valuation consultancy, service development and operation using satellite data

Main clients
Water: Tokyo city, Aomori city, Fukushima city
Agriculture: Shinmei Corporation, Seiwa Corporation
Telecommunication: Nippon Telegraph and Telephone East Corporation

Tenchijin welcomes any inquiries from companies in the water-related business sector. (contact email: , person in charge: Keitaro Asaba)

Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025

  • Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment
  • Etrasimod demonstrates robust efficacy across multiple endpoints, including mucosal healing, endoscopic normalization, and histological remission
  • Safety profile remains consistent with previous studies, with no new safety findings were observed

SHANGHAI, Feb. 26, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the presentation of maintenance data from its multi-center Phase III clinical study of etrasimod (VELSIPITY®) in Asia at the 20th European Crohn’s and Colitis Organization Congress (ECCO 2025).

Etrasimod, a next-generation, once-daily selective sphingosine-1-phosphate (S1P) receptor modulator, is being developed for the treatment of moderately to severely active ulcerative colitis (UC). To date, etrasimod is the only advanced UC therapy that has completed a large-scale, randomized, controlled pivotal study in the Asia-Pacific region. The findings of the ES101002 study provide robust evidence supporting the use of etrasimod in UC patients.

The positive results come from a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of etrasimod conducted in the Asian region. This is the largest pivotal Phase 3 study to date in Asian population with moderately to severely active ulcerative colitis. A total of 340 eligible patients with an inadequate response to, loss of response to, or intolerance to at least 1 prior UC treatment were randomized in a 2:1 ratio to receive either etrasimod 2mg once daily or placebo for 12 weeks in the induction period. All patients who completed the induction treatment and were responders at week 12 entered a 40-week maintenance period in which patients were re-randomized in a 1:1 ratio to receive etrasimod 2mg once-daily or placebo for up to 40 weeks.

The results demonstrate that treatment with etrasimod 2 mg resulted in a clinically meaningful and statistically significant improvement in the primary and all secondary endpoints at the end of maintenance period. A statistically significant greater proportion of etrasimod-treated patients achieved clinical remission at Week 40 compared with placebo (etrasimod: 48.1%; placebo: 12.5%; difference = 35.9%; 95% CI: [22.5%, 49.2%]; 2-sided p value < 0.0001).  A statistically significant greater proportion of etrasimod-treated patients achieved endoscopic improvement (etrasimod: 61.0%; placebo: 15.0%, difference = 46.6% [95% CI : 33.2%,60.1%], 2-sided p value < 0.0001) and clinical response (etrasimod: 79.2%; placebo: 35.0%, difference = 45.6% [ 95% CI :31.9%,59.3%], 2-sided p value < 0.0001) at week 40 compared with placebo. Other secondary endpoints of mucosal healing, endoscopic normalization, and histological remission also significantly favored patients treated with etrasimod compared with placebo. Notably, mucosal healing as measured by a central read endoscopic subscore≤ 1 (excluding friability) with a Geboes Index score < 2.0, was achieved in 51.9% of the etrasimod treated patients compared to 8.8% in the placebo group (2-sided p-value <0.0001). The safety profile of etrasimod during the maintenance period was consistent with previous studies, with no new safety findings observed.

“The positive results of etrasimod’s maintenance data presented at one of the world’s leading academic conferences on inflammatory bowel disease further confirms its advantages as an innovative therapy for UC,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Autoimmune diseases have always been a key research focus for Everest. We are committed to enhancing the accessibility and clinical application of etrasimod, and moving forward, we aim to expand its availability across Asia to benefit more appropriate patients.”

“As the only drug that has been proven to be effective in UC patients with moderately to severely active isolated proctitis in the global Phase III ELEVATE clinical trials, in the results of the Asian multi-center Phase 3 clinical trial of etrasimod for the treatment of moderately to severely active UC, etrasimod achieved positive topline data results in both the induction and maintenance treatment periods.” said Prof. Wu Kaichun at the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial.“As a next-generation selective S1P receptor modulator, once-daily oral etrasimod has a rapid onset of action, significantly increases the proportion of patients with clinical remission,endoscopic normalization and mucosal healing, and helps patients to reach their treatment goals sooner. We look forward to more patients with ulcerative colitis benefiting from etrasimod in the future.”

As a core product of Everest Medicines, etrasimod is an innovative and advanced therapy that provides rapid onset of action, clinical remission and mucosal healing through an oral, once-daily regimen. Etrasimod has been commercially launched in Macau in 2024. The new drug application has also been officially accepted in mainland China and Hong Kong, and etrasimod has officially been approved for adult patients with moderately to severely active UC by the Guangdong Provincial Medical Products Administration and can be used in the medical institutions designated by the Connect Policy in the Greater Bay Area, The first prescription in mainland Guangdong, Foshan, has been issued for the drug in the Greater Bay Area.

About VELSIPITY® (etrasimod)

VELSIPITY® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK, Switzerland, Israel and Macau, China for VELSIPITY® in ulcerative colitis.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

STAK Inc. Announces Pricing of Initial Public Offering

CHANGZHOU, China, Feb. 26, 2025 /PRNewswire/ — STAK Inc. (the “Company” or “STAK”), a fast-growing company specializing in the research, development, manufacturing, and sale of oilfield-specialized production and maintenance equipment, today announced the pricing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares at a public offering price of US$4.00 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on February 26, 2025, under the ticker symbol “STAK.” The Offering is expected to close on or about February 27, 2025, subject to the satisfaction of customary closing conditions.

The Company expects to receive aggregate gross proceeds of US$5 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 ordinary shares, representing 15% of the ordinary shares sold in the Offering, at the public offering price less underwriting discounts.

The Offering is being conducted on a firm commitment basis. Kingswood Capital Partners, LLC is acting as the representative of the underwriter.

A registration statement on Form F-1 relating to the Offering was filed with the Securities and Exchange Commission (the “SEC”) (File Number: 333-283258), as amended, and was declared effective by the SEC on February 25, 2025. The Offering is being made only by means of a prospectus forming a part of the registration statement. Copies of the prospectus relating to the Offering may be obtained, when available, from Kingswood Capital Partners, LLC at 7280 W Palmetto Park Rd., Suite 301, Boca Raton, FL 33433, or via email at bherman@kingswoodus.com, or telephone at (561) 961-0505. In addition, copies of the prospectus relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

Before you invest, you should read the registration statement and the preliminary prospectus contained therein and the final prospectus, when available, and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About STAK Inc.

STAK Inc. is a fast-growing company specializing in the research, development, manufacturing, and sale of oilfield-specific production and maintenance equipment. The Company designs and manufactures oilfield-specialized production and maintenance equipment, then collaborates with qualified specialized vehicle manufacturing companies to integrate the equipment onto vehicle chassis, producing specialized oilfield vehicles for sale. Additionally, the Company sells oilfield-specialized equipment components, related products, and provides automation solutions. Its vision is to help oilfield services companies reduce costs and increase efficiency by providing the cutting-edge integrated oilfield equipment and automation solutions service. Its mission is to become a powerful provider for the niche markets of specialized oilfield vehicles and equipment in China. For more information, please visit the Company’s website at https://www.stakindustry.com/ir/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “potential,” “intend,” “plan,” “believe,” “likely to” or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

STAK Inc.
Investor Relations Department
Email: ir@stakindustry.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

10 Restaurants unite to celebrate Japanese White Day with a passionate culinary experience featuring Red Gold Canned Tomatoes from Europe

TOKYO, Feb. 26, 2025 /PRNewswire/ — In an exciting collaboration, ANICAV is proud to announce a week-long promotion in honour of Japanese White Day, showcasing ten distinct menus crafted around the theme of EU and Italian canned tomatoes. This unique culinary event will take place from 14 to 24 March 2025 at ten participating restaurants, each offering a diverse selection of dishes inspired by the rich red colour and nutritious properties of EU and Italian canned tomatoes.

Pizza Margherita with Red Gold Tomatoes from Europe.
Pizza Margherita with Red Gold Tomatoes from Europe.

Japanese White Day, traditionally celebrated on 14 March, is a time for expressing affection and appreciation. In the spirit of this celebration, each restaurant will present its own interpretation of the theme, focusing on the health benefits of tomatoes and their versatility in the kitchen.

Featured Menus from each Restaurant:

  1. ape cucina naturale: Start with Acquacotta (a soup with Red Gold tomatoes and egg) followed by a Timballo of naturally-grown vegetables.  Continue your meal with some whole wheat spaghetti with Red Gold tomatoes, beets and saffron sauce. Choose between a Red Gold tomato cashew nut tart or a Brodetto (a rich savoury dish made with seafood and Red Gold tomatoes).  For dessert, enjoy a Red Gold tomato and chocolate framboise parfait.
  2. Babbo Angelo: Antipasti misti (including cold tomato soup) to start.  Three types of pasta follow (Spaghetti alla Norma, Lasagna with Red Gold tomato sauce, plus your choice of savoury or cream sauce pasta). Enjoy their signature Pizza Marinara and Pizza Margherita, featuring a vibrant tomato base followed, if you wish, by the catch of the day fish with a Red Gold tomato salmoriglio sauce or Ezo venison steak.  Finish your dinner with assorted desserts and coffee.
  3. Suranje: An amuse bouche with some Red Gold tomato delights and a Red Gold Chijimi (Korean pancake) to start. Enjoy a Korean barbecue and Red Gold Bibimbap (Korean mixed rice with vegetables).
  4. Nakameguro Grill: A vibrant Foie gras terrine brùlée with tomato paste on toast enjoy while waiting for a Tomato and soy-bean milk bavarois with extra virgin olive oil and rock salt.  As your main, choose between Steamed seafood and tomatoes with aroma of herbs or a Tomato ragù of aged shorthorn beef with grilled vegetables from Miura.  End your dinner with a delicious Basque burnt cheesecake with tomato confiture sauce.
  5. Pizzeria Bar Trico: Savour a warm caprese on a concentrate of Red Gold tomatoes while waiting for a Red Gold Sakura shrimp pizza followed by a reconstruction of Amatriciana fresh pasta with Yanbaru bacon from Okinawa and Red Gold tomatoes.
  6. Pizzeria GTalia da Filippo: A Red Gold from Europe non-alcoholic sparkling drink or sparkling wine will be followed by a Red Gold Margherita pizza with buffalo mozzarella and a Red Gold tomato Linguine alla pescatora. Enjoy a hearty Braised beef cheek and red wine stew featuring Red Gold canned tomatoes and end your dinner with a refreshing Red Gold tomato ice-cream.
  7. Ristorante EN: Enjoy a filled plant-shaped puff pastry appetiser and EN’s style Red Gold tomato starter. Continue with a Minestrone soup made from naturally-grown vegetables and Cappellini pasta with saffron.  End your dinner with a dessert and some petit fours.
  8. Se Son Rose: Assorted seasonal vegetables to start, followed by a Caprese tomato soup with Italian mozzarella and Pasta with ragù sauce made with Akagi beef. End your dinner with a Forest fruit tart with Red Gold tomato sorbet.
  9. Hakkou Café Shoutatei: After a Red Gold tomatoes tofu appetiser, enjoy Root vegetable fried balls with Hakkou fermented Red Gold tomatoes and a Spiced chicken curry with Red Gold Koji (malted rice) tomatoes.  Finish your dinner with your loved one with an Amazake ice cream.
  10. Vegetable and Bar Linio: Stewed seasonal vegetables and vegetable gratin with Red Gold tomato demi-glace sauce to start. To follow: vegetable risotto and Red Gold tomato rice flour noodles, fusing Italian and Japanese flavours, showcasing rice, noodles and a rich tomato sauce. For dessert, enjoy a raw cacao brownie.

Throughout the week, the restaurant clients are encouraged to not only indulge in delicious meals but also learn about the health benefits of tomatoes, which are rich in vitamins A and C, potassium, and lycopene, promoting overall wellness and vitality.

“By uniting these ten restaurants, we aim to provide an extraordinary culinary experience that celebrates the love and appreciation central to White Day, while also highlighting the nutrition that canned tomatoes bring to our health,” said Giovanni De Angelis. ANICAV’s General Director. “We are excited to invite the Japanese community to enjoy this unique festival of flavours.”

Reservations are highly recommended for this special event. For more details, including the restaurant locations and menus on offer, please visit our website https://redgoldfromeurope.jp https://anicav.it https://redgoldfromeurope.jp/news/press-tasting-and-lunch-dinner-for-red-gold-from-europe-restaurant-week/

ABOUT RED GOLD FROM EUROPE & ANICAV

Red Gold is the name of the EU (European Union) programme to raise awareness about EU preserved (canned) tomatoes 100% Made in Europe.

ANICAV – The Italian Association of Canned Vegetable Industries – members account for over 60% of all the processed tomatoes in Italy, and nearly all of the whole peeled tomatoes produced.

Join us this March for a week of passion, nutrition, and exceptional flavours!

For more information about Red Gold from Europe, visit our website https://redgoldfromeurope.jp

Follow us on:

Facebook: https://www.facebook.com/redgoldjapan

Instagram: https://www.instagram.com/redgoldjp/

X: https://x.com/RedGoldJapan1

YouTube: https://www.youtube.com/@redgoldfromeuropejp

 


Photo – https://laotiantimes.com/wp-content/uploads/2025/02/pizza_margherita.jpg

Photo – https://laotiantimes.com/wp-content/uploads/2025/02/visual_asia-1.jpg

LG Innotek Enters the Market with Automotive AP Modules, Boosting Its Semiconductor Component Business

  • Surging demand for automotive semiconductor components for ADAS and digital cockpits in
    the era of connected cars
  • 400 components, including chipsets and memory, squeezed into a single 2.5 inches x 2.5 inches module
  • “Aiming for mass production in the second half of 2025 and facilitating efforts to build a solid business portfolio”

SEOUL, South Korea, Feb. 25, 2025 /PRNewswire/ — LG Innotek (CEO Moon Hyuksoo) announced on February 25 that it will launch a new electronic component for vehicles, the Automotive Application Processor Module(AP Module), targeting automotive semiconductor component markets worldwide. This move will enable the company to expand its existing electronic components business into the automotive semiconductor sector.

LG Innotek employees are showcasing the Automotive AP module
LG Innotek employees are showcasing the Automotive AP module

Automotive AP modules are semiconductor components installed in vehicles to integrate and control automotive electronic systems such as Advanced Driver Assistance Systems(ADAS) and digital cockpits. They serve as the vehicle’s brain, similar to a computer’s Central Processing Unit (CPU).

With the advancements made in connected cars, such as autonomous driving capabilities, the demand for AP modules is increasing rapidly every year. This is because the Printed Circuit Board(PCB)-based semiconductor chips used in existing vehicles cannot efficiently process the vast amounts of data generated by digital cockpits equipped with advanced ADAS and high-resolution displays.

According to industry estimates, the number of AP modules installed in vehicles worldwide is expected to grow by 22% annually, from a total of 33 million this year to 113 million by 2030.

The greatest advantage of LG Innotek’s Automotive AP Module is its compact size.

The compact module measuring 2.5 inches x 2.5 inches contains more than 400 components, including a memory semiconductor, Power Management Integrated Circuit(PMIC), and integrated chipset(SoC∙System on Chip), which controls various systems such as data and graphics processing, display output, and multimedia.

The application of this product makes it possible to shrink the size of existing motherboards, enhancing design flexibility of automaker clients. It also shortens the signal distance between the highly integrated components in the module, further improving the module’s control performance.

LG Innotek’s plan is to continue to enhance its Automotive AP Module. This year, it aims to increase the module’s heat dissipation performance, enabling it to operate at up to 95˚C, and significantly shorten the AP module development period by predicting warpage through virtual simulation.

LG Innotek is currently promoting the product to global semiconductor companies in North America and other regions, hoping to start mass-producing it in the second half of this year.

CEO Moon Hyuksoo commented, “The development of Automotive AP modules has enabled us to accelerate the expansion of our semiconductor components business.” He added, “LG Innotek will continue to develop products that deliver unique customer value and establish itself as a reliable technology partner for its global customers.”

LG Innotek is planning to grow its semiconductor components business to 3 billion dollars in annual sales by 2030, largely based on high-value semiconductor substrates such as FC-BGA(Flip-Chip Ball Grid Array), RF-SiP(Radio Frequency-System in Package) and Automotive AP modules.

[Terminology]

Digital Cockpit: Digital Cockpit refers to devices installed in vehicles, such as cutting-edge dashboards and Head-Up Displays(HUDs). Previously, digital cockpits offered additional functions, such as navigation, but they now also provide a comprehensive range of information, including data on the air conditioning system and vehicle condition.

 

The Automotive AP module developed by LG Innotek
The Automotive AP module developed by LG Innotek

The Automotive AP module developed by LG Innotek
The Automotive AP module developed by LG Innotek

Bybit Takes Aim at Crypto Crime with Launch of Industry-first LazarusBounty.com Platform

DUBAI, UAE, Feb. 26, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, today announced the launch of LazarusBounty.com, an industry-first bounty platform that represents a decisive, four-pronged offensive against crypto crime. Underpinned by the firm belief that information transparency is key, LazarusBounty.com is designed to expose illicit activity, hold hackers accountable, and secure digital assets with unparalleled speed and precision.


Information Transparency at the Heart of 4-pronged Ultimate Defense

At the core of LazarusBounty.com is the conviction that complete, real-time transparency empowers the community and transforms the fight against cybercrime. By making every action visible and every transaction traceable, Bybit ensures that the truth is the most powerful weapon against hackers.

1. Powered by Comprehensive On-Chain Security Data

LazarusBounty.com consolidates premier blockchain security databases—including resources from Chainalysis, Arkham, GoPlus, and other top security companies—into a definitive, real-time security wiki. This robust integration empowers investigators and the broader community with critical insights needed to expose and counter illicit transactions.

2. Immediate Activation of Panel of Expert Investigations

When a large-scale breach is reported, LazarusBounty.com mobilizes elite blockchain detectives — such as ZachXBT and Yu Xian (C), founder of SlowMist — to initiate immediate, rigorous investigations. This expert-driven approach serves as a call for those dedicated to unmasking cybercriminals.to arms for those dedicated to unmasking cybercriminals.

3. Decentralized Security Alliance Council on Hand to Consult

Bybit has enlisted chief security officers from major public chains to serve as advisors, forming a formidable, decentralized network that stands united against cybercrime. This alliance reinforces the company’s commitment to transparency and accountability across the blockchain ecosystem.

4. Merit-Based Bounty Reward Leaderboard 

The platform’s Hack Leaderboard meticulously tracks contributions and allocates rewards based on the effectiveness of each input in recovering stolen funds. Every verified piece of evidence is logged, spotlighting the bounty hunters actively dismantling criminal operations while exposing those who stand by without contributing.

LazarusBounty.com will also be equipped with an automated notification system that triggers immediate remedial measures once illicit funds are traced to their endpoints. By instantly alerting relevant platforms to freeze or block these assets, the system eliminates the delays associated with manual intervention—ensuring that every second counts in the fight against cybercrime.

Ben Zhou, Co-founder and CEO of Bybit, hopes to send a clear message. “In today’s blockchain landscape, transparency isn’t just a principle—it’s our most potent weapon against cybercrime. With LazarusBounty.com, we are taking a stand to ensure that every transaction is visible and every hacker is held accountable. Our multifive-pronged offensive is a clear message: if you steal, you will be found, and justice will be swift,” said Zhou.

A Proactive Stance Against Cybercrime

The launch of LazarusBounty.com sends a clear, unyielding message: stolen funds will not be tolerated for illegal use. This platform serves as a direct challenge to cybercriminals—a warning that any attempt to exploit the blockchain for illicit purposes will be met with relentless, coordinated action. With this five-pronged offensive, Bybit not only challenges cybercriminals but also sets a new industry standard. Rather than waiting for problems to escalate, Bybit is taking the lead in securing the ecosystem and calls on every vigilant community member to support this mission.

#Bybit / #TheCryptoArk 

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 60 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

The Australian Photoageing Re.Port uncovers Australia’s blind spot-on sun damage and skin health, taking unexpected emotional toll

SYDNEY, Feb. 26, 2025 /PRNewswire/ — The inaugural Re.Think Skin: Australian Photoageing Re.Port reveals six out of 10 Australians are unaware that sun exposure is the biggest contributor to visible facial ageing, despite evidence showing it accounts for up to 80% of visible skin ageing.[1] The nationwide YouGov survey, commissioned by iNova Pharmaceuticals with support from Australasian Society of Cosmetic Dermatologists (ASCD), highlights the need for greater awareness and management of photoageing: premature skin ageing caused by sun exposure[2] – to address both the visible and psychological toll of sun damaged skin.

Before / After treatment pigmentation (Credit: Praewphan - stock.adobe.com)
Before / After treatment pigmentation (Credit: Praewphan – stock.adobe.com)

The survey of 1,565 Australians revealed notable generational differences in awareness and attitudes toward photoageing- a condition that accelerates the skin’s natural ageing process and leads to changes that make the skin appear older than it naturally would.[2,3]

  • Only one in four Australians have heard of the term ‘photoageing’
  • Younger Australians (Gen Z) are less likely to understand sun exposure’s role in facial ageing compared to older generations
  • Men are less likely than women to recognise sun exposure as the primary contributor to facial ageing

The psychological impact of photoageing is substantial:

  • Two-thirds (66%) feel facial ageing signs make them feel older than they are
  • 62% report facial ageing signs affect their confidence
  • 57% experience anxiety about facial ageing signs
  • Younger Australians (Gen Z and Millennials) report higher levels of concern and anxiety about facial ageing signs than older generations

Despite high awareness of sun damage risks, prevention remains low:

  • While nearly 9 in 10 Australians understand sun can cause skin damage, fewer than 1 in 5 consistently wear protective clothing or sunscreen
  • Only 13% always use sunscreen on their faces when outdoors
  • Misconceptions about tanning are more prevalent among younger generations
  • This finding is consistent with a previous study in Queensland that revealed as much as 80% (1,400 respondents) aged 20 to 54 years had signs of photoageing.

Barriers to seeking photoageing treatment include:

  • Cost concerns (64% of respondents)
  • Worries about potential side effects (32%)
  • Lack of knowledge about treatment options (29%)
  • Only 46% would consult a doctor about signs of photoageing

Professor Greg Goodman AM, President of the Australasian Society of Cosmetic Dermatologists said: “The Australian Photoageing Re.Port highlights issues defined in previous reports that Australian women show signs of facial ageing up to 20 years earlier than women in the US,[4] making this a particularly relevant health concern for our population.”

“We recognise the significance of this survey in raising disease awareness around photoageing and its impact on skin health and wellbeing in Australia. This report is a call to action for Australians to prioritise skin health discussions with healthcare providers to help address both the visible and psychological impacts of photoageing,” concluded Professor Goodman.

“The Australian Photoageing Re.Port highlights a critical gap in public awareness regarding the impact of sun exposure on skin ageing and emotional wellbeing,” said Temi Stavroulakis, Director of Medical and Regulatory Affairs ANZ, at iNova Pharmaceuticals. “By shedding light on these findings, we aim to empower Australians to take proactive steps in protecting their skin health and wellbeing.”

References

1.  Flament F et al. Effect of the sun on visible clinical signs of aging in Caucasian skin. Clin Cosmet Investig Dermatol 2013;6:221-232.

2.  Australasian College of Dermatologists. Ageing skin. https://www.dermcoll.edu.au/atoz/ageing-skin (accessed November 2024).

3.  Canadian Dermatology Association. Photoaging. https://dermatology.ca/public-patients/skin/photoaging (accessed November 2024).

4.  Goodman GJ et al. Comparison of self-reported signs of facial ageing among Caucasian women in Australia versus those in the USA, the UK and Canada. Australas J Dermatol. 2017;59(2):108–117.

5.  Green AC, Hughes MC, McBride P, Fourtanier A. Factors associated with premature skin aging (photoaging) before the age of 55: a population-based study. Dermatology. 2011;222(1):74-80.

About The Australian Photoageing Re.Port: The report is based on a survey conducted online by YouGov Plc between 9-15 October 2024, sampling 1,565 Australians aged 18 years and older. The data was weighted to be representative of the Australian population. The full report can be accessed from www.rethinkskin.com.au/resources 

About iNova Pharmaceuticals:

iNova Pharmaceuticals is leading the way to better health by constantly searching for new, practical solutions that improve the everyday health and wellbeing of people around the world.

Our portfolio of market-leading consumer health brands and prescription medicines are backed by science and span across the key therapeutic areas of throat, cough, cold & flu, skin health & sun protection, pain management, wound care, weight management and natural health supplements among others. Headquartered in Singapore, today our products are distributed in over 75 markets across Asia, Australia, New Zealand, Middle East & Africa and Europe.

Learn more at www.inovapharma.com.au.

About The Australasian Society of Cosmetic Dermatologists (ASCD): 

The Australasian Society of Cosmetic Dermatologists (ASCD) is an internationally recognised professional organisation, dedicated to advancing cosmetic and procedural dermatology. Through provision of education, the ASCD enhances industry expertise, innovation and optimises patient care.

Learn more at www.ascd.org.au.